GE Showcases Breast Tomosynthesis Solution
GE will demonstrate at RSNA 2014 its newly FDA-approved tomosynthesis solution.
GE Healthcare will showcase at RSNA 2014 its new breast imaging 3D tomosynthesis solution, SenoClaire.
SenoClaire, which received FDA approval in August, uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, which removes the potential from motion from the tube helping to preserve microcalcification sharpness and avoid image blur, GE said.
The SenoClaire has no increase in dose from a 2D standard mammogram to a 3D view, GE said.
[[{"type":"media","view_mode":"media_crop","fid":"29834","attributes":{"alt":"GE SenoClaire","class":"media-image media-image-right","id":"media_crop_954194364083","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3114","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 240px; width: 300px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"GE SenoClaire","typeof":"foaf:Image"}}]]
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
